iBio, Inc. (IBIO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IBIO Revenue Growth
Revenue Breakdown (FY 2021)
IBIO's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
IBIO Revenue Analysis (2014–2025)
As of May 8, 2026, iBio, Inc. (IBIO) generated trailing twelve-month (TTM) revenue of $300,000, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q2 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, IBIO's 5-year compound annual growth rate (CAGR) stands at -24.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $2.4 million in 2021.
Revenue diversification analysis shows IBIO's business is primarily driven by Ibio Cdmo (54%), and Ibio Inc (46%). With over half of revenue concentrated in Ibio Cdmo, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ADMA (+11.0% YoY), HALO (+37.6% YoY), and NVAX (-52.5% YoY), IBIO has underperformed the peer group in terms of revenue growth. Compare IBIO vs ADMA →
IBIO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IBIOCurrent | $300,000 | -100.0% | -24.6% | -4650.5% | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% |
IBIO Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $400K | +77.8% | $400K | 100.0% | $-18,602,000 | -4650.5% |
| 2024 | $225K | - | $225K | 100.0% | $-16,634,000 | -7392.9% |
| 2023 | $0 | -100.0% | $0 | - | $-29,343,000 | - |
| 2022 | $1.9M | -20.5% | $-1,907,000 | -101.2% | $-29,697,000 | -1576.3% |
| 2021 | $2.4M | +44.7% | $909K | 38.3% | $-31,111,000 | -1312.1% |
| 2020 | $1.6M | -18.8% | $935K | 57.1% | $-14,003,000 | -854.9% |
| 2019 | $2.0M | +354.5% | $2.0M | 100.0% | $-15,788,000 | -782.4% |
| 2018 | $444K | +12.7% | $444K | 100.0% | $-14,227,000 | -3204.3% |
| 2017 | $394K | -58.4% | $394K | 100.0% | $-14,274,000 | -3622.8% |
| 2016 | $948K | -48.8% | $948K | 100.0% | $-9,893,000 | -1043.6% |
See IBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IBIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IBIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIBIO — Frequently Asked Questions
Quick answers to the most common questions about buying IBIO stock.
Is IBIO's revenue growth accelerating or slowing?
IBIO revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of -24.6%. TTM revenue fell to $300000.00. This reverses the prior growth trend.
What is IBIO's long-term revenue growth rate?
iBio, Inc.'s 5-year revenue CAGR of -24.6% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is IBIO's revenue distributed by segment?
IBIO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.